Navigation Links
Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Date:1/9/2008

ng a child. In addition, women treated with Vidaza should not nurse.

About Pharmion

Pharmion is a leading global oncology company uniquely focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at http://www.pharmion.com.

About MethylGene

MethylGene Inc. (TSX: MYG) is a publicly-traded biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer. The Company's lead product, MGCD0103, is an oral isotype-selective HDAC inhibitor presently in multiple clinical trials for solid tumors and hematological malignancies, including Phase 2 monotherapy and Phase 1 and Phase 2 combination trials with Vidaza(R), Gemzar(R) and Taxotere(R). MGCD265 is an oral kinase inhibitor targeting the c-Met, Tie-2, Ron and VEGF receptor tyrosine kinases. In addition, MethylGene has several preclinical programs: MGCD290 an HDAC inhibitor in combination with azoles for fungal infections; an HDAC program for Huntington's disease; and a sirtuins program for cancer. MethylGene's development and commercialization partners include Pharmion Corporation, Taiho Pharmaceutical and EnVivo Pharmaceuticals. Please visit our website at http://www.methylgene.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements relating to the planned development program for MGCD0103, which express the current beliefs and expectations of management. Such statements are based on current expectations and invol
'/>"/>

SOURCE Pharmion Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
3. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
4. Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
5. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
6. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
7. Elekta Announces Clinical Start-Up of New Leksell Gamma Knife(R) Perfexion(TM) at UPMC
8. InterMune Announces Start of Phase 1b Trial of ITMN-191
9. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
10. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
11. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2008)...RNewswire-FirstCall/ -- Eli Lilly and Company,(NY...g Application (sNDA) from,the U.S. Food and Drug ...Cl),for the management of chronic pain. Lilly pla...of 2009, adding data from a recently completed pos... knee. , The decision does not affect dulox...
(Date:11/25/2008)...prove recovery , , Audio and Web Video Reso... Mayo Clinic News Blog. Please see the bottom of t..., Minn., Nov. 25 A Mayo...don,t think they,re having a stroke -- and as a re...ion worsens. The findings appear in the current is...
(Date:11/25/2008)...25 Pharmacyclics, Inc.,... has completed a Phase 1,clinical trial with PCI-...molecule Factor VIIa inhibitor. The trial was cond...ate the safety and pharmacologic effect of,PCI-27... in a linear dose,response in the International N...
(Date:11/24/2008)...4 Leaders of Schering-Pl...update for investors on the company,s research pip...o that includes 46 new entities in clinical trials...studies. , , "Research and development is a...e continue our transformation," said Fred Hassan, ...
Breaking Medicine Technology:Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Do You Know You're Having a Stroke? 2Do You Know You're Having a Stroke? 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 2Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 2Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 5LI COR Introduces the Odyssey 28R 29 Two Color NIR Fluorescent Protein Molecular Weight Marker 8270 1LI COR Introduces the Odyssey 28R 29 Two Color NIR Fluorescent Protein Molecular Weight Marker 8270 2Cephalon Launches National Consumer Awareness Initiative on Appropriate Use of Prescription Opioid Medications 8265 1Cephalon Launches National Consumer Awareness Initiative on Appropriate Use of Prescription Opioid Medications 8265 2Sysmex Announces Clinical Laboratory Software Name Change 8261 1Solos Endoscopy Inc in Final Stages to Upgrade Pink Sheet Status from Limited to Current Information 8256 1Solos Endoscopy Inc in Final Stages to Upgrade Pink Sheet Status from Limited to Current Information 8256 2
... PASADENA, Calif.--(BUSINESS WIRE)--Mar 20, 2007 -...unced today that,majority-owned subsidiary Calando...eedings of the National Academy of Sciences,(PNAS)...ple,systemic dosing with Calando,s lead siRNA the...ary technologies in targeted,polymeric delivery sy...
... Iontophoretic Drug Delivery System, dermal patch ... and epinephrine (IDDS), SEATTLE, March 20, 2007...arma") Seattle, WA, a transdermal drug delivery co...ous Technologies, Inc.,("TTI"), Tokyo, Japan ann...nology, which administers lidocaine and epinephrin...
Other Medicine Technology:Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on,Targeted, Systemic Delivery of siRNA 2Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on,Targeted, Systemic Delivery of siRNA 3Dharma Therapeutics Shows IDDS Is Effective in Reducing Pain,Associated With Insertion of an Intravenous Catheter in Their Phase,2 Clinical Trial 2Dharma Therapeutics Shows IDDS Is Effective in Reducing Pain,Associated With Insertion of an Intravenous Catheter in Their Phase,2 Clinical Trial 3
(Date:12/1/2008)... nicotine use, personality illnesses common, study...ws) -- Psychiatric disorders are common among youn...ent, a new report shows. , To reach this findin...,000 respondents, aged 19 to 25, who took part in ...elated Conditions. , The study found that 45.8 ...
(Date:12/1/2008)...see problems with the agency,s goals, commitment a...hDay News) -- Responding to criticism that it has ...ply, the U.S. Food and Drug Administration release... consumers. , Among the most important changes ...r relationships with state and local health depart...
(Date:12/1/2008)...analysis of the National Cancer Institute,s cancer...der women experience delayed or incomplete radiati...and that this suboptimal care can lead to worse ou...ll Medical College and colleagues found that among...0 breast cancer registry patients aged 65 and olde...
(Date:12/1/2008)...ELLE, N.Y., Dec. 1 Due to the urge...n the field of AIDS/HIV research and clinical care...vide complimentary access to all archival online i...nd of December in honor of World AIDS Day. Free on...nd STDs ( www.liebertpub.com/apc ) and AIDS Re...
Breaking Medicine News(10 mins):Health News:Few Young Adults Seek Treatment for Psych Disorders 2Health News:FDA Touts Efforts to Enhance Food Safety 2Health News:FDA Touts Efforts to Enhance Food Safety 3Health News:FDA Touts Efforts to Enhance Food Safety 4Health News:Delays in radiation therapy lead to increased breast cancer recurrence 2Health News:Mary Ann Liebert, Inc. Provides Free Online Journal Access in Recognition of World AIDS Day 2
...new head of the Ontario Medical Association has ma...t priority. // He has asked the provincial govern...nadian-trained doctors working in the US to come h...nine thousand physicians who were trained in Canad...
...among doctors working in the radiological departme...cher and assistant professor at the Department of ...and Medical Center has come up with a new techniqu...t would not obstruct their movement and would allo...
...lth service is losing more than ?50m because of pe...te years of similar complaint by NHS managers the ...sson from Hinchingbrooke Hospital in Huntingdon sa... do not turn up as they feel better while others f...
...shown that cutting back a few calories from our di...event certain age related changes in cells. // S...te on Aging have found that eating a little less f...a lifespan can reduce or even reverse aging-relate...
Other Medicine News:Health News:Ontario Medical Association Planning To Lure Back Expat Doctors 2Health News:Cut Calories to Age Gracefully 2Health News:Cut Calories to Age Gracefully 3
Integrated electronics, single-chip CCD camera with PAL and NTSC output. PAL output at 460 lines, NTSC output at 470 lines, focal length 30mm. 90mm length x 20mm diameter.
Large image and wide-angle design.
Large-image field with titanium couplers for c-mount scopes. 30mm focal length.
High intensity lamp with built-in, switchable spare lamp. Low-noise fan with reduced air turbulence.
Medicine Products: